Shares of Niagen Bioscience (NAGE) surged 5.09% during intraday trading on Tuesday, as investors reacted to a recent analyst report highlighting the stock's potential undervaluation. The report, which analyzed undervalued stocks based on cash flows, placed NAGE among the top 10 undervalued stocks in the United States.

According to the analysis, Niagen Bioscience is currently trading at $9.82, significantly below its estimated fair value of $19.02. This suggests a potential discount of 48.4%, making it an attractive option for value investors. The report's findings may have prompted increased buying interest, contributing to the stock's notable rise.

While specific company news for Niagen Bioscience was not provided, the broader market context shows investors are currently seeking opportunities in undervalued stocks amidst market fluctuations and uncertain economic conditions. As the U.S. markets navigate potential shifts in monetary policy and inflationary trends, stocks like NAGE that offer a significant discount to their estimated fair value may be garnering increased attention from bargain-hunting investors.